Navigation Links
Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
Date:11/5/2008

PRINCETON, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it has received a milestone payment of an undisclosed amount from its licensing partner, Centocor R&D Inc., for the completion of a Phase 2 trial of CNTO 95, a fully human antibody targeting the integrin receptors that are implicated in tumor-induced angiogenesis. The CNTO 95 human antibody was generated using Medarex's UltiMAb(R) technology. Medarex may receive future milestone payments and royalties should this product candidate progress to commercialization and achieve commercial sales.

"We are pleased with the progress of this program and the potential of technology licensing programs under our partnership with Centocor to contribute to future revenues," said Howard H. Pien, President and CEO of Medarex.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
2. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
3. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
4. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
5. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
8. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
9. Medarex Announces Ipilimumab Program Continues to Move Forward
10. Medarex to Receive Milestone Payment from Amgen
11. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Calif., Oct. 27 ... beamforming technology, analog-front-end semiconductors and solutions for the ... Ultrasound Beamforming Development Kit.  Based on Samplify,s AutoFocus™ ... solution for the ultrasound front end, from probe ...
... Oct. 27 Solos Endoscopy, Inc. (Pink Sheets: ... revenues during the three months ended September 30, 2010 in ... ended September 30, 2009.  This was an increase of 34.8% for ... Despite a down global economy, Solos has been able ...
Cached Medicine Technology:Samplify's New Medical Ultrasound Development Kit Accelerates Equipment Time to Market By Up to 12 Months 2Samplify's New Medical Ultrasound Development Kit Accelerates Equipment Time to Market By Up to 12 Months 3Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010 2
(Date:4/22/2014)... release is available in German . ... important intracellular signaling molecules, but their mode of action ... of cellular function and behavior, while at high concentrations ... and DNA. To analyze how redox signaling unfolds in ... microscopy technique has been developed jointly by the teams ...
(Date:4/22/2014)... help rein in massive health care spending, a new ... find ways to incentivize pharmaceutical companies and device makers ... of examining existing medical technologies and their use, a ... what drugs and medical devices get created in the ... care spending with as little loss of health as ...
(Date:4/22/2014)... all seem to know who we say is neurotic and ... unable to act but simply doesn,t want to., ... of nearly 4,000 college students in 19 countries has uncovered ... and moving forward with life. Turns out that when they ... don,t like it as much as non-neurotics. Therefore persuasive communications ...
(Date:4/22/2014)... demonstrated the first size-based form of chromatography that ... living cells. This unique physical approach to probing ... whether a cell lives or dies, remains normal ... conventional microscopy. , "We,ve developed membrane-embedded nanodot array ... probe and manipulate membrane assemblies, including signaling clusters, ...
(Date:4/22/2014)... release is available in German . ... Laboratories of the University of Vienna and the Medical University ... now shown how double stranded RNA, such as viral genetic ... During the immune response against viral infection, the protein ADAR1 ... it modifies viral RNA to inhibit reproduction of the virus. ...
Breaking Medicine News(10 mins):Health News:Neuroimaging: Live from inside the cell 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:Neurotics don't just avoid action: They dislike it 2Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
... known to be harmful. Some of them like malaria can ... make the host female less fertile. A recent study has ... The vivacious Wolbachia is actually giving the host a boost ... ,This new study reveals the Symbiotic or mutually ...
... of the transgender community in India is highly aware of ... a survey by a Chennai-based NGO. ,"Most ... transmitted diseases and AIDS. As much as 99 percent said ... said they used condoms during sexual activity," said R. Isabel, ...
... help cut back on how much food and calories you eat ... show that when participants in the study ate a first course ... intake at lunch by 20 percent, compared to when they did ... studies about consuming lower-calorie soup as a way to reduce food ...
... are no more likely than other children to have ... ,Researchers compared blood samples of 34 children with autism ... been referred to an outpatient clinic of the same ... detect celiac diseaseanti-gliadin antibodies and anti-endomysial antibodies. Biopsies of ...
... improve symptoms of moderate to severe chronic obstructive pulmonary ... ,The results of the randomized, double-blind, ... issue of the May American Journal of Respiratory and ... ,According to an editorial commenting on the ...
... A study finds that sleep deprivation can adversely affect ... the expectation of gains and making light of ... understand the neural underpinnings of risky decision making under ... Duke University studied healthy volunteers as they underwent functional ...
Cached Medicine News:Health News:Useful Parasites 2Health News:Awareness About HIV/AIDS is High Among the Transgenders: Survey 2Health News:Taking Low-calorie Soup Before Meal Will Help Cut Calories at Meals 2Health News:Anti-inflammatory Drug Fails to Improve COPD Symptoms 2Health News:Sleep Deprivation can Affect Competent Decision-making 2
REFRESH TEARS® lubricating eye drops does more than just smoothe and relieve dry, irritated eyes. REFRESH TEARS® creates a shield of protection against further irritation with its unique, lon...
... feel dry, scratchy, or irritated, you want ... REFRESH PLUS® lubricant eye drops for mild ... what youre looking for. A couple of ... crave with a special formula that has ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
...
Medicine Products: